A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
OPEN TO ACCRUAL
II
NCT06773936
rabin.niroula@BrownHealth.org
